A 64-year-old man with type 2 diabetes, prior myocardial infarction and eGFR 48 mL/min/1.73 m² is on metformin and basal insulin. His HbA1c is 7.8%. A...

Question

A 64-year-old man with type 2 diabetes, prior myocardial infarction and eGFR 48 mL/min/1.73 m² is on metformin and basal insulin. His HbA1c is 7.8%. According to updated Diabetes Canada recommendations, which additional antihyperglycaemic agent would best address his cardiovascular and renal risk?

Accepted Answer

Add an SGLT2 inhibitor with proven cardiovascular and renal benefit

Answer

Add a sulfonylurea

Answer

Add a DPP-4 inhibitor

Answer

Switch metformin to a thiazolidinedione

Answer

Add acarbose

ca-mccqe1 MCQ (SBA): Type 2 diabetes with cardiovascular disease

A 64-year-old man with type 2 diabetes, prior myocardial infarction and eGFR 48 mL/min/1.73 m² is on metformin and basal insulin. His HbA1c is 7.8%. According to updated Diabetes Canada recommendations, which additional antihyperglycaemic agent would best address his cardiovascular and renal risk?